BR112022008580A2 - Métodos para tratar transtornos depressivos - Google Patents
Métodos para tratar transtornos depressivosInfo
- Publication number
- BR112022008580A2 BR112022008580A2 BR112022008580A BR112022008580A BR112022008580A2 BR 112022008580 A2 BR112022008580 A2 BR 112022008580A2 BR 112022008580 A BR112022008580 A BR 112022008580A BR 112022008580 A BR112022008580 A BR 112022008580A BR 112022008580 A2 BR112022008580 A2 BR 112022008580A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- depressive disorders
- treat depressive
- human
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
MÉTODOS PARA TRATAR TRANSTORNOS DEPRESSIVOS. Em certas modalidades, a presente invenção é direcionada a métodos para tratar transtornos depressivos em um humano, em que os métodos compreendem administrar oralmente uma quantidade terapeuticamente eficaz de N-[4-(6-fluoro-3,4-di-hidro-1H-isoquinolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Composto A), ao humano em necessidade do mesmo. A presente invenção é adicionalmente direcionada a vários métodos melhorados de terapia e administração do Composto A.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962932724P | 2019-11-08 | 2019-11-08 | |
PCT/US2020/059481 WO2021092439A1 (en) | 2019-11-08 | 2020-11-06 | Methods of treating depressive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022008580A2 true BR112022008580A2 (pt) | 2022-08-09 |
Family
ID=73643360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022008580A BR112022008580A2 (pt) | 2019-11-08 | 2020-11-06 | Métodos para tratar transtornos depressivos |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210161886A1 (pt) |
EP (1) | EP4054580A1 (pt) |
JP (1) | JP2022553569A (pt) |
KR (1) | KR20220098746A (pt) |
CN (1) | CN114667146A (pt) |
AU (1) | AU2020380961A1 (pt) |
BR (1) | BR112022008580A2 (pt) |
CA (1) | CA3155812A1 (pt) |
CL (1) | CL2022001102A1 (pt) |
CO (1) | CO2022008001A2 (pt) |
CR (1) | CR20220250A (pt) |
IL (1) | IL292678A (pt) |
MA (1) | MA56607A1 (pt) |
MX (1) | MX2022005490A (pt) |
PE (1) | PE20221766A1 (pt) |
TW (1) | TW202128162A (pt) |
WO (1) | WO2021092439A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3207191A1 (en) | 2021-02-09 | 2022-08-18 | Simon Neil PIMSTONE | Voltage-gated potassium channel opener for use in treating anhedonia |
US20220288057A1 (en) * | 2021-02-09 | 2022-09-15 | Xenon Pharmaceuticals Inc. | Conjoint therapy for treating seizure disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2420960T3 (es) * | 2006-08-23 | 2013-08-28 | Valeant Pharmaceuticals International | Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio |
US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
-
2020
- 2020-11-06 MX MX2022005490A patent/MX2022005490A/es unknown
- 2020-11-06 CN CN202080077815.3A patent/CN114667146A/zh active Pending
- 2020-11-06 WO PCT/US2020/059481 patent/WO2021092439A1/en active Application Filing
- 2020-11-06 EP EP20816351.9A patent/EP4054580A1/en active Pending
- 2020-11-06 PE PE2022000702A patent/PE20221766A1/es unknown
- 2020-11-06 BR BR112022008580A patent/BR112022008580A2/pt unknown
- 2020-11-06 JP JP2022524695A patent/JP2022553569A/ja active Pending
- 2020-11-06 MA MA56607A patent/MA56607A1/fr unknown
- 2020-11-06 AU AU2020380961A patent/AU2020380961A1/en active Pending
- 2020-11-06 TW TW109138929A patent/TW202128162A/zh unknown
- 2020-11-06 CR CR20220250A patent/CR20220250A/es unknown
- 2020-11-06 KR KR1020227017725A patent/KR20220098746A/ko unknown
- 2020-11-06 CA CA3155812A patent/CA3155812A1/en active Pending
- 2020-11-09 US US17/093,183 patent/US20210161886A1/en active Pending
-
2022
- 2022-04-29 CL CL2022001102A patent/CL2022001102A1/es unknown
- 2022-05-02 IL IL292678A patent/IL292678A/en unknown
- 2022-06-06 CO CONC2022/0008001A patent/CO2022008001A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020380961A1 (en) | 2022-05-26 |
CR20220250A (es) | 2022-08-19 |
WO2021092439A1 (en) | 2021-05-14 |
MX2022005490A (es) | 2022-08-10 |
US20210161886A1 (en) | 2021-06-03 |
PE20221766A1 (es) | 2022-11-11 |
CO2022008001A2 (es) | 2022-06-10 |
TW202128162A (zh) | 2021-08-01 |
IL292678A (en) | 2022-07-01 |
CA3155812A1 (en) | 2021-05-14 |
EP4054580A1 (en) | 2022-09-14 |
KR20220098746A (ko) | 2022-07-12 |
MA56607A1 (fr) | 2022-10-31 |
CL2022001102A1 (es) | 2023-01-27 |
CN114667146A (zh) | 2022-06-24 |
JP2022553569A (ja) | 2022-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
BR112019005930A2 (pt) | combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas | |
BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
BR112022008580A2 (pt) | Métodos para tratar transtornos depressivos | |
EA201591610A1 (ru) | Ингибиторы кинуренинового пути | |
BR112015005117A2 (pt) | métodos de tratamento da doença de alzheimer e suas composições farmacêuticas | |
BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
PH12020551898A1 (en) | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener | |
WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
BR112021021826A2 (pt) | Terapias de combinação compreendendo os inibidores de apremilast e tyk2 | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
BR112016013734A2 (pt) | Composto, composição farmacêutica, kit, e uso de um composto | |
BR112022010733A2 (pt) | Métodos para tratar dor | |
BR112022016360A2 (pt) | Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos | |
BR112021017314A2 (pt) | Uso de extrato de elaeocarpus sylvestris | |
BR112023023030A2 (pt) | Composições e métodos para o tratamento de depressão | |
BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
BR112015023806A2 (pt) | Novos regimes de dosagem de celgosivir para o tratamento de dengue | |
BR112022005881A2 (pt) | Compostos de benzoxazinona como inibidores duplos de klk5/7 | |
CO2023011948A2 (es) | Terapia conjunta para el tratamiento de trastornos convulsivos | |
CL2021002846A1 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
BR112022010540A2 (pt) | Métodos para tratar sintomas comportamentais e psicológicos em pacientes com demência | |
MX2022006630A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso. |